Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Cash & Equivalents

Cash & Equivalents at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$102.06M-44.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
Zymeworks logo
ZymeworksZYME
$244.28M+221%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$509M-2.7%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$451.8M+323%
Quest Diagnostics logo
Quest DiagnosticsDGX
$393M+109%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S4×-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's cash & equivalents?
ADMA Biologics (ADMA) reported cash & equivalents of $138.15M in Q1 2026.
How has ADMA Biologics's cash & equivalents changed year-over-year?
ADMA Biologics's cash & equivalents increased by 92.9% year-over-year, from $71.63M to $138.15M.
What is the long-term trend for ADMA Biologics's cash & equivalents?
Over 5 years (2020 to 2025), ADMA Biologics's cash & equivalents has grown at a 9.4% compound annual growth rate (CAGR), from $55.92M to $87.63M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.